Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 28, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	2,354	3,882	3,926	3,248	5,732	9,158
Market Cap Growth	-40.95%	-1.13%	20.88%	-43.33%	-37.41%	271.16%
Enterprise Value	2,769	3,991	4,355	3,149	5,183	8,768
Last Close Price	24.44	42.07	47.82	46.33	84.09	138.43
PS Ratio	3.78	6.93	9.04	8.94	16.31	33.79
PB Ratio	256.89	14.80	14.26	9.21	6.21	7.93
P/TBV Ratio	-	119.17	60.65	21.95	7.67	9.36
EV/Sales Ratio	4.39	7.12	10.03	8.67	14.75	32.35
Debt / Equity Ratio	53.41	3.47	3.39	2.57	0.43	0.33
Asset Turnover	0.46	0.37	0.29	0.24	0.21	0.19
Inventory Turnover	16.63	19.62	22.84	34.15	35.05	34.01
Quick Ratio	1.59	2.13	2.32	3.04	4.33	6.51
Current Ratio	1.89	2.37	2.61	3.38	4.72	6.83
Return on Equity (ROE)	-313.43%	-211.71%	-193.22%	-110.96%	-43.72%	-20.64%
Return on Assets (ROA)	-24.92%	-22.37%	-23.43%	-26.44%	-14.54%	-14.25%
Return on Capital Employed (ROCE)	-64.00%	-46.20%	-47.00%	-50.50%	-28.50%	-21.00%
Earnings Yield	-24.63%	-14.66%	-15.45%	-21.78%	-7.92%	-2.04%
FCF Yield	-19.18%	-10.86%	-13.22%	-15.29%	-7.18%	-1.92%
Buyback Yield / Dilution	-12.26%	-23.11%	-5.19%	-3.13%	-11.42%	-7.54%

Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q